[0064]

[Item 44]

A method for treating and/or preventing cancer in a subject in need thereof, comprising administering a therapeutically and/or prophylactically effective amount of the compound or the pharmaceutically acceptable salt thereof of any one of items 1 to 30, or the pharmaceutical composition of any one of items 31 and 33 to 41, or the liposome of item 32, or the therapeutic agent and/or prophylactic agent of any one of items 42 to 43, to the subject.

[0065]

[Item 45]

The method of item 44, wherein the cancer is at least one type of cancer selected from the group consisting of acute leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, polycythemia vera, malignant lymphoma, plasma cell tumor, multiple myeloma, myelodysplastic syndrome, brain tumor, head and neck cancer, esophageal cancer, thyroid cancer, small cell lung cancer, non-small cell lung cancer, thymoma/thymic carcinoma, breast cancer, gastric cancer, gallbladder/bile duct cancer, liver cancer, hepatocellular carcinoma, pancreatic cancer, colon cancer, rectal cancer, anal cancer, gastrointestinal stromal tumor, choriocarcinoma, endometrial cancer, cervical cancer, ovarian cancer, bladder cancer, prostate cancer, urothelial cancer, renal cancer, renal cell cancer, testicular tumor, testicular germ cell tumor, ovarian germ cell tumor, Wilms tumor, skin cancer, malignant melanoma, neuroblastoma, osteosarcoma, Ewing sarcoma, and soft tissue sarcoma.

[0066]

[Item 46]

Use of the compound or the pharmaceutically acceptable salt thereof of any one of items 1 to 30, or the pharmaceutical composition of any one of items 31 and 33 to 41, or the liposome of item 32, or the therapeutic agent and/or prophylactic agent

of any one of items 42 to 43, for the manufacture of therapeutic agent and/or prophylactic agent for cancer.

[0067]

[Item 47]

The use of the compound or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition, or the liposome, or the therapeutic agent and/or prophylactic agent of item 46, wherein the cancer is at least one type of cancer selected from the group consisting of acute leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, polycythemia vera, malignant lymphoma, plasma cell tumor, multiple myeloma, myelodysplastic syndrome, brain tumor, head and neck cancer, esophageal cancer, thyroid cancer, small cell lung cancer, non-small cell lung cancer, thymoma/thymic carcinoma, breast cancer, gastric cancer, gallbladder/bile duct cancer, liver cancer, hepatocellular carcinoma, pancreatic cancer, colon cancer, rectal cancer, anal cancer, gastrointestinal stromal tumor, choriocarcinoma, endometrial cancer, cervical cancer, ovarian cancer, bladder cancer, prostate cancer, urothelial cancer, renal cancer, renal cell cancer, testicular tumor, testicular germ cell tumor, ovarian germ cell tumor, Wilms tumor, skin cancer, malignant melanoma, neuroblastoma, osteosarcoma, Ewing sarcoma, and soft tissue sarcoma.

[0068]

[Item 48]

The compound or the pharmaceutically acceptable salt thereof of any one of items 1 to 30, or the pharmaceutical composition of any one of items 31 and 33 to 41, or the liposome of item 32, or the therapeutic agent and/or prophylactic agent of any one of items 42 to 43 for use in the treatment and/or prophylaxis of cancer.

[0069]

[Item 49]

The compound or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition, or the liposome, or

the therapeutic agent and/or prophylactic agent of item 48, wherein the cancer is at least one type of cancer selected from the group consisting of acute leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, polycythemia vera, malignant lymphoma, plasma cell tumor, multiple myeloma, myelodysplastic syndrome, brain tumor, head and neck cancer, esophageal cancer, thyroid cancer, small cell lung cancer, non-small cell lung cancer, thymoma/thymic carcinoma, breast cancer, gastric cancer, gallbladder/bile duct cancer, liver cancer, hepatocellular carcinoma, pancreatic cancer, colon cancer, rectal cancer, anal cancer, gastrointestinal stromal tumor, choriocarcinoma, endometrial cancer, cervical cancer, ovarian cancer, bladder cancer, prostate cancer, urothelial cancer, renal cancer, renal cell cancer, testicular tumor, testicular germ cell tumor, ovarian germ cell tumor, Wilms tumor, skin cancer, malignant melanoma, neuroblastoma, osteosarcoma, Ewing sarcoma, and soft tissue sarcoma.

[0070]

[Item 50]

The compound or the pharmaceutically acceptable salt thereof of any one of items 1 to 30, or the liposome of item 32, or the pharmaceutical composition of any one of items 31 and 33 to 41, or the therapeutic agent and/or prophylactic agent of any one of items 42 to 43, for treating cancer in concomitant use with a concomitantly used medicament or a pharmaceutically acceptable salt thereof, wherein the concomitantly used medicament is at least one selected from the group consisting of a hormonal therapy agent, a chemotherapeutic agent, an immunotherapeutic agent, and an agent that inhibits a cell growth factor or its receptor action.

[0071]

[Item 51]

The compound or the pharmaceutically acceptable salt thereof of any one of items 1 to 30, or a pharmaceutical composition comprising the liposome of item 32, or the

pharmaceutical composition of any one of items 31 and 33 to 41, or the therapeutic agent and/or prophylactic agent of any one of items 42 to 43, comprised as a combination with a concomitantly used medicament, wherein the concomitantly used medicament is at least one selected from the group consisting of a hormonal therapy agent, a chemotherapeutic agent, an immunotherapeutic agent, and an agent that inhibits a cell growth factor and its receptor action.

[0072]

[Item 52]

A combination of the compound or the pharmaceutically acceptable salt thereof of any one of items 1 to 30, or the liposome of item 32, or the pharmaceutical composition of any one of items 31 and 33 to 41, or the therapeutic agent and/or prophylactic agent of any one of items 42 to 43 with a concomitantly used medicament, wherein the concomitantly used medicament is at least one selected from the group consisting of a hormonal therapy agent, a chemotherapeutic agent, an immunotherapeutic agent, and an agent that inhibits a cell growth factor and its receptor action.

[0073]

[Item 53]

The compound or the pharmaceutically acceptable salt thereof of any one of items 1 to 30, or the liposome of item 32, or the pharmaceutical composition of any one of items 31 and 33 to 41, or the therapeutic agent and/or prophylactic agent of any one of items 42 to 43, wherein the compound or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition, or the liposome, or the therapeutic agent and/or prophylactic agent is administered in combination with a concomitantly used medicament or a pharmaceutically acceptable salt thereof, and wherein the concomitantly used medicament is at least one selected from the group consisting of a hormonal therapy agent, a chemotherapeutic agent, an immunotherapeutic

p is preferably 0, 1 or 2.

p is more preferably 0 or 1.

p is still more preferably 0.

[0128]

q is preferably 1 or 2.

q is more preferably 1.

[0129]

r is preferably 0, 1 or 2.

r is more preferably 1 or 2.

r is still more preferably 2.

[0130]

Among the compounds represented by formula (1), the preferred compounds are the following compounds or pharmaceutically acceptable salts thereof.

[0131]

Among the compounds represented by formula (1) or formula (1'), the preferred embodiment is the following (A).

(A) A compound or a pharmaceutically acceptable salt thereof wherein

R^1 is a C_{1-6} alkyl group (the alkyl group is optionally substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a C_{6-10} aryl group, a hydroxy group, a carboxyl group, a sulfinic acid group, a sulfonic acid group, a phosphoric acid group, C_{1-6} alkoxy, $-NR^4R^5$, $-CO_2R^4$, $-CONR^4R^5$, $-SO_2R^4$ and $-SO_2NR^4R^5$),

R^2 and R^3 are the same or different, each independently a hydrogen atom, or a C_{1-6} alkyl group (the alkyl group is optionally substituted with 1 to 3 substituents selected from the group consisting of a fluorine atom and C_{1-6} alkoxy),

R^4 and R^5 are the same or different, each independently a hydrogen atom, or a C_{1-6} alkyl group optionally substituted with 1 to 2 substituents selected from the group consisting of a fluorine atom and a carboxyl group, wherein R^4 and R^5, if both are C_{1-10} alkyl groups, together with the nitrogen to which they